Restrictions on coverage of obesity drugs are affecting patients, prompting them to make changes. The involvement of telehealth companies in obesity drug treatment has raised concerns among primary care doctors. The development of weight-loss drugs has also led to shifts in lobbying strategies and may impact various industries beyond healthcare.